Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

DSNKY
주식 순위 #660
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports,... Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
주가
$17.64
시가총액
$32.65B
변동 (1일)
-3.24%
변동 (1년)
-23.70%
국가
JP
거래 Daiichi Sankyo Company, Limited (DSNKY)

카테고리

Daiichi Sankyo Company, Limited (DSNKY)의 배당 이력
Daiichi Sankyo Company, Limited (주식 심볼: DSNKY)은 총 36회의 배당금을 지급했습니다.
모든 배당금의 합계 (주식 분할 반영): $7.57
배당 수익률 (TTM): 0.0245
Daiichi Sankyo Company, Limited (DSNKY)의 2009부터 2026까지 배당 지급 내역
연간 배당 지급
연도 배당금 (주식 분할 조정됨) 변화
2026 (TTM) $0.2424 -46.06%
2025 $0.4494 16.09%
2024 $0.3871 58.39%
2023 $0.2444 16.66%
2022 $0.2095 -13.25%
2021 $0.2415 1.13%
2020 $0.2388 11.07%
2019 $0.215 2.87%
2018 $0.209 0.14%
2017 $0.2087 5.51%
2016 $0.1978 -43.47%
2015 $0.3499 -36.15%
2014 $0.548 -14.11%
2013 $0.638 -45.88%
2012 $1.18 52.19%
2011 $0.7746 7.33%
2010 $0.7217 -5.08%
2009 $0.7603 0.00%
모든 배당 지급 목록
연도 배당금 변화
2026 (TTM) $0.2424 -46.06%
2025 $0.4494 16.09%
2024 $0.3871 58.39%
2023 $0.2444 16.66%
2022 $0.2095 -13.25%
2021 $0.2415 -66.29%
2020 $0.7165 11.10%
2019 $0.6449 2.85%
2018 $0.627 0.14%
2017 $0.6261 5.51%
2016 $0.5934 4.77%
2015 $0.5664 3.34%
2014 $0.5481 -8.44%
2013 $0.5986 -83.08%
2012 $3.54 368.46%
2011 $0.755 9.23%
2010 $0.6912 -9.09%
2009 $0.7603 0.00%
유사 기업 또는 경쟁사의 배당 지급
회사 배당 지급 횟수 국가
215.00%
US
67.00%
GB
225.00%
US
53.00%
US
32.00%
CH